Montag Caldwell Lowers stake in Thermo Fisher Scientific (TMO)

Thermo Fisher Scientific (TMO) : Montag Caldwell reduced its stake in Thermo Fisher Scientific by 19.47% during the most recent quarter end. The investment management company now holds a total of 1,148,007 shares of Thermo Fisher Scientific which is valued at $168,722,589 after selling 277,480 shares in Thermo Fisher Scientific , the firm said in a disclosure report filed with the SEC on May 3, 2016.Thermo Fisher Scientific makes up approximately 3.13% of Montag Caldwell’s portfolio.

Other Hedge Funds, Including , Motco boosted its stake in TMO in the latest quarter, The investment management firm added 342 additional shares and now holds a total of 44,679 shares of Thermo Fisher Scientific which is valued at $6,566,473. Thermo Fisher Scientific makes up approx 0.78% of Motco’s portfolio.Nippon Life Insurance Co reduced its stake in TMO by selling 209 shares or 0.97% in the most recent quarter. The Hedge Fund company now holds 21,439 shares of TMO which is valued at $3,150,890. Thermo Fisher Scientific makes up approx 0.08% of Nippon Life Insurance Co’s portfolio.Rockefeller Financial Services Inc boosted its stake in TMO in the latest quarter, The investment management firm added 4,148 additional shares and now holds a total of 20,565 shares of Thermo Fisher Scientific which is valued at $2,966,501. Thermo Fisher Scientific makes up approx 0.06% of Rockefeller Financial Services Inc’s portfolio.Gw Henssler Associates Ltd reduced its stake in TMO by selling 11,271 shares or 14.98% in the most recent quarter. The Hedge Fund company now holds 63,954 shares of TMO which is valued at $9,391,645. Thermo Fisher Scientific makes up approx 1.09% of Gw Henssler Associates Ltd’s portfolio.

Thermo Fisher Scientific opened for trading at $148.36 and hit $148.8899 on the upside on Tuesday, eventually ending the session at $148.83, with a gain of 0.93% or 1.37 points. The heightened volatility saw the trading volume jump to 14,71,477 shares. Company has a market cap of $58,566 M.

On the company’s financial health, Thermo Fisher Scientific reported $1.80 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $1.74. The company had revenue of $4294.80 million for the quarter, compared to analysts expectations of $4113.28 million. The company’s revenue was up 9.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.63 EPS.

Many Wall Street Analysts have commented on Thermo Fisher Scientific. Company shares were Reiterated by Mizuho on May 3, 2016 to “Buy”, Firm has raised the Price Target to $ 163 from a previous price target of $160 .Thermo Fisher Scientific was Downgraded by Jefferies to ” Hold” on Apr 29, 2016. Company shares were Reiterated by Mizuho on Apr 4, 2016 to “Buy”, Firm has raised the Price Target to $ 160 from a previous price target of $150 .

Thermo Fisher Scientific Inc. is a provider of analytical instruments equipment reagents and consumables software and services for research manufacturing analysis discovery and diagnostics. The company operates through four segments: Life Sciences Solutions provides reagents instruments and consumables used in biological and medical research discovery and production of new drugs and vaccines as well as diagnosis of disease; Analytical Instruments provides instruments consumables software and services that are used in the laboratory; Specialty Diagnostics offers diagnostic test kits reagents culture media instruments and associated products and Laboratory Products and Services offers self-manufactured and sourced products for the laboratory.

Leave a Reply

Thermo Fisher Scientific - Is it time to Sell?

Top Brokerage Firms are advising their investors on Thermo Fisher Scientific. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.